亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Depemokimab reduces asthma exacerbations similarly to other biologics

医学 哮喘恶化 哮喘 重症监护医学 梅德林 内科学 临床试验 呼吸道疾病 系统回顾 支气管扩张药 荟萃分析 疾病严重程度 随机对照试验 最小临床重要差异 吸入性皮质类固醇
作者
ARNAUD AB BOURDIN,Ian Douglas Pavord,Nicholas Ballew,Butcher Brandon,Lydia Vinals,H. El Alili,Vikas Jangra,Victor Laliman-Khara,Grammati Sarri,Anna Vichiendilokkul,Peter Howarth,Rafael Alfonso-Cristancho
出处
期刊:Annals of Allergy Asthma & Immunology [Elsevier BV]
卷期号:137 (3): 329-339.e7 被引量:1
标识
DOI:10.1016/j.anai.2026.05.018
摘要

BACKGROUND: Depemokimab is the first ultra-long-acting biologic, with efficacy and safety recently reported in the Phase III SWIFT-1/-2 studies, which included patients with type 2 asthma. OBJECTIVE: To estimate the relative efficacy and safety of depemokimab vs other biologics via an indirect treatment comparison. METHODS: The indirect treatment comparison evidence base was compiled via a systematic literature review to identify randomized clinical trials on the efficacy and safety of biologics in patients with severe asthma. End points were analyzed using network meta-analysis (unadjusted) and multi-level network meta-regression (partially or fully adjusted for clinically relevant or statistically feasible covariates, including prior exacerbation history, inhaled or oral corticosteroid use, and blood eosinophil count) and included annualized exacerbation rates (AERs), adverse events (AEs), and serious AEs (SAEs). RESULTS: Overall, 17 and 22 trials were included in the exacerbation and safety analyses, respectively. Significant differences in efficacy were observed in the unadjusted fixed-effect model for depemokimab vs placebo, omalizumab, benralizumab, and dupilumab 300 mg and in the partially adjusted fixed-effect model for depemokimab vs placebo and omalizumab. In the fully adjusted fixed-effect model, depemokimab significantly reduced AERs vs placebo; no significant differences were observed between depemokimab and other biologics in this model. The odds of experiencing AEs and SAEs were similar across treatments, with fewer SAEs observed with depemokimab than with dupilumab. The results were generally consistent across fixed- and random-effect approaches. CONCLUSION: In general, no statistically significant difference was detected between depemokimab and other biologics in terms of AER reduction or safety in severe asthma, including when adjusting for differences across studies in clinically important patient characteristics.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
阔达之卉完成签到 ,获得积分10
5秒前
欢喜的小蕾完成签到,获得积分10
9秒前
纯情的阁发布了新的文献求助10
17秒前
45秒前
忧郁血茗完成签到,获得积分10
45秒前
58秒前
1分钟前
丰富的雅绿完成签到,获得积分10
1分钟前
1分钟前
帅气寄风完成签到,获得积分10
1分钟前
1分钟前
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
bkagyin的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
顾矜的应助被纯情的阁采纳,获得30
1分钟前
1分钟前
刻苦绿蕊完成签到,获得积分10
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
丘比特的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.4的应助被纯情的阁采纳,获得10
1分钟前
田様的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
科研通AI6.2的应助被纯情的阁采纳,获得10
1分钟前
1分钟前
agathahqs的应助被纯情的阁采纳,获得10
1分钟前
上官若男的应助被落润晓采纳,获得10
1分钟前
1分钟前
务实的香薇完成签到,获得积分10
1分钟前
2分钟前
2分钟前
缥缈的觅风完成签到 ,获得积分10
2分钟前
Eva小飞鱼发布了新的文献求助10
2分钟前
2分钟前
落润晓发布了新的文献求助10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158827
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552000
邀请新用户注册赠送积分活动 2471370